. 2021 Jun 22;10(7):755. doi: 10.3390/antibiotics10070755

Table 4.

Resistance phenotype, number of isolates, collection period, and antimicrobial activity of streptococci for tedizolid and linezolid.

Microorganism/Study	Antimicrobial	Resistance Phenotype	Nº Isolates	Collection Period	Percent of Isolates (%) Inhibited at MIC (mg/L) of:
*S. pneumoniae*					0.094	0.125	0.19	0.25	0.38
Hipp et al. [29]	Tedizolid	Penicillin-susceptible	56	2009–2016	1.8	3.6	57.1	35.7	1.8
					MIC (mg/L)
					0.064	0.125	0.25	0.5	1	2	4
EUCAST [30]	Linezolid		60,180			0.1	1.0	7.8	65.3	25.9
					MIC (mg/L)
Pfaller et al. [25]					0.015	0.03	0.06	0.12	0.25	0.5	1
	Tedizolid		1273	2014–2015	0.3	0.5	6.4	72.5	20.2
Streptococcus spp.					MIC (mg/L)
Zurenko et al. ^a [23]					0.06	0.12	0.25	0.5	1	2	4
	Tedizolid		1600	2008–2013	5.00	44.38	50.13	0.50
	Linezolid		1600	2008–2013			3.50	26.13	65.13	5.19	0.06
S. anginosus group
Zurenko et al. ^b [23]	Tedizolid		91	2008–2013	38.46	43.96	17.58
	Linezolid		91	2008–2013			38.46	35.16	26.37
S. viridans group
Pfaller et al. ^c [25]	Tedizolid		218	2014–2015	38.53	59.17	2.29
β-hemolytic streptococci
Pfaller et al. ^d [25]	Tedizolid			2014–2015	93.5	4.5

^a Includes S. pyogenes, S. agalactiae, S. groups C, F, and G, and S. viridans group; ^b Includes isolates of S. anginosus, S. intermedius, and S. constellatus; ^c Includes S. anginosus, S. anginosus group, S. australis, S. constellatus, S. cristatus, S. gordonii, S. infantis, S. lutetiensis, S. massiliensis, S. mitis, S. mitis group, S. mitis/oralis, S. mutans, S. oralis, S. parasanguinis, S. salivarius, S. salivarius group, and S. sanguinis. ^d Includes S. agalactiae, S. canis, S. dysgalactiae, and S. pyogenes. Light grey: values under the susceptibility range.